{"schema_version":"1","generated_at":"2026-10-28T18:52:01.888Z","data_as_of":null,"url":"https://www.findmykol.com/kol/paul-mathew-ma-2","json_url":"https://www.findmykol.com/kol/paul-mathew-ma-2/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"paul-mathew-ma-2","name":"Paul Mathew","credential":"MD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"Boston","state":"MA","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1447341284"},"summary":"Paul Mathew is an Oncology physician. ClinicalTrials.gov lists 7 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"note":"Research metrics are not shown for this record: either no confident publication match for this name, or more than one clinician shares the matched author record."},"trials":{"count":7,"shown":3,"withheld":5,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT04425538","title":"A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).","phase":"PHASE2","status":"COMPLETED","role":"Overall official","sponsor":"Tufts Medical Center","source_url":"https://clinicaltrials.gov/study/NCT04425538","trial_url":"https://www.findmykol.com/trial/NCT04425538"},{"nct":"NCT03737370","title":"Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer","phase":"PHASE1","status":"COMPLETED","role":"Overall official","sponsor":"Tufts Medical Center","source_url":"https://clinicaltrials.gov/study/NCT03737370","trial_url":"https://www.findmykol.com/trial/NCT03737370"},{"nct":"NCT02500901","title":"Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)","phase":"PHASE1","status":"TERMINATED","role":"Overall official","sponsor":"Paul Mathew, MD","source_url":"https://clinicaltrials.gov/study/NCT02500901","trial_url":"https://www.findmykol.com/trial/NCT02500901"}],"source":"trials"},"payments":{"company_count":9,"program_years":{"first":2021,"last":null},"rows_total":16,"shown":3,"withheld":13,"rows":[{"payer":"Lundbeck LLC","program_year":2025,"amount_usd":263.21,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1447341284"},{"payer":"Axsome Therapeutics, Inc.","program_year":2025,"amount_usd":131.19,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1447341284"},{"payer":"ABBVIE INC.","program_year":2025,"amount_usd":68.95,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1447341284"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1447341284","source":"payments"},"prescribing":{"data_year":2024,"areas_total":1,"areas_shown":1,"areas":[{"area":"Cancer & immunology","share_pct":100,"classes_total":1,"classes":[{"class":"Androgen Receptor Inhibitor","setting":"prescribed","share_pct":100,"drugs":[{"name":"Xtandi","share_pct":60.7},{"name":"Bicalutamide","share_pct":39.3}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":0,"facility_pct":100},"source":"medicare"},"funding":{"award_count":1,"fiscal_years":{"first":2020,"last":2024},"rows_total":5,"shown":3,"withheld":2,"matched_by":"principal investigator name at an organization in the practice state","rows":[{"project":"R01CA245864","title":"Control of lethal prostate cancer with a bispecific av and a5b1 integrin antibody","fiscal_year":2024,"amount_usd":"497137","organization":"TUFTS MEDICAL CENTER","source_url":"https://reporter.nih.gov/quickSearch/R01CA245864"},{"project":"R01CA245864","title":"Control of lethal prostate cancer with a bispecific av and a5b1 integrin antibody","fiscal_year":2023,"amount_usd":"497984","organization":"TUFTS MEDICAL CENTER","source_url":"https://reporter.nih.gov/quickSearch/R01CA245864"},{"project":"R01CA245864","title":"Control of lethal prostate cancer with a bispecific av and a5b1 integrin antibody","fiscal_year":2022,"amount_usd":"467360","organization":"TUFTS MEDICAL CENTER","source_url":"https://reporter.nih.gov/quickSearch/R01CA245864"}],"source":"grants"},"contact":{"address_1":"800 WASHINGTON ST","city":"Boston","state":"MA","zip":"021111552","phone":"617-636-5000","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1447341284","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":5,"payments":13,"funding":2}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2015-05-07","collected_at":"2026-10-27T00:00:00.000Z"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"}},"methodology_url":"https://www.findmykol.com/about#methodology"}